Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 3/20 | 0.44 |
| ▸ | DRD5 | P21918 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31505344 | 1.00 | ESR2 (0.46) | ESR2ESR1DRD2DRD4ALDH1A1 | |
| SCHEMBL12549679 | 0.80 | PARP10 (0.42) | ALDH1A1MAPTRECQLTDP1CYP3A4 | |
| SCHEMBL1952868 | 0.79 | MAPT (0.39) | ALDH1A1MAPTRECQLTDP1CYP3A4 | |
| SCHEMBL29554315 | 0.79 | MAPT (0.39) | ALDH1A1MAPTRECQLTDP1CYP3A4 | |
| SCHEMBL25287433 | 0.79 | HTR2C (0.42) | ALDH1A1MAPTRECQLTDP1CYP3A4 | |
| SCHEMBL11888458 | 0.78 | ALDH1A1 (0.63) | DRD2DRD4ALDH1A1MAPTRECQL | |
| SCHEMBL5306224 | 0.77 | DRD2 (0.46) | ESR2ESR1DRD2DRD4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21326128 | 0.77 | MAPT (0.38) | ALDH1A1MAPTRECQLTDP1CYP3A4 | |
| SCHEMBL19454256 | 0.77 | NR3C1 (0.44) | ESR2ESR1DRD2DRD4ALDH1A1 | |
| SCHEMBL20883895 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MAPTRECQLTDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101738-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| EP-2590910-A2 | FLUORINE RADIOLABELLING PROCESS | Isis Innovation Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004567-A2 | FLUORINE RADIOLABELLING PROCESS | ISIS INNOVATION LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004567-A2 | FLUORINE RADIOLABELLING PROCESS | ISIS INNOVATION LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190529-A1 | Fluorine Radiolabelling Process | ESRRG, NR5A2, RXFP4 | ESR2 36/4885ESR1 78/4885DRD2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.